MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF

MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF

The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing/presentation machinery (APM) ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PALOMEQUE ALARCON, José Ángel, ALBANELL MESTRES, Joan, PÉREZ NÚÑEZ, Iván, SERRA MIR, Gabriel, CELIÀ TERRASSA, Antoni
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator PALOMEQUE ALARCON, José Ángel
ALBANELL MESTRES, Joan
PÉREZ NÚÑEZ, Iván
SERRA MIR, Gabriel
CELIÀ TERRASSA, Antoni
description The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing/presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4431153A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4431153A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4431153A13</originalsourceid><addsrcrecordid>eNrjZHD0DQ1x9AsJVvB3U3BU8PF0d_Rz0XVxDXD1c3H1C1Fw9g9yDQhyDQ72D1LQ8AHyNBWAChRCg12DFUI8XINc_d14GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakm8a4CJibGhoamxo6ExEUoAXBcqJw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF</title><source>esp@cenet</source><creator>PALOMEQUE ALARCON, José Ángel ; ALBANELL MESTRES, Joan ; PÉREZ NÚÑEZ, Iván ; SERRA MIR, Gabriel ; CELIÀ TERRASSA, Antoni</creator><creatorcontrib>PALOMEQUE ALARCON, José Ángel ; ALBANELL MESTRES, Joan ; PÉREZ NÚÑEZ, Iván ; SERRA MIR, Gabriel ; CELIÀ TERRASSA, Antoni</creatorcontrib><description>The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing/presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240918&amp;DB=EPODOC&amp;CC=EP&amp;NR=4431153A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240918&amp;DB=EPODOC&amp;CC=EP&amp;NR=4431153A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PALOMEQUE ALARCON, José Ángel</creatorcontrib><creatorcontrib>ALBANELL MESTRES, Joan</creatorcontrib><creatorcontrib>PÉREZ NÚÑEZ, Iván</creatorcontrib><creatorcontrib>SERRA MIR, Gabriel</creatorcontrib><creatorcontrib>CELIÀ TERRASSA, Antoni</creatorcontrib><title>MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF</title><description>The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing/presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHD0DQ1x9AsJVvB3U3BU8PF0d_Rz0XVxDXD1c3H1C1Fw9g9yDQhyDQ72D1LQ8AHyNBWAChRCg12DFUI8XINc_d14GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakm8a4CJibGhoamxo6ExEUoAXBcqJw</recordid><startdate>20240918</startdate><enddate>20240918</enddate><creator>PALOMEQUE ALARCON, José Ángel</creator><creator>ALBANELL MESTRES, Joan</creator><creator>PÉREZ NÚÑEZ, Iván</creator><creator>SERRA MIR, Gabriel</creator><creator>CELIÀ TERRASSA, Antoni</creator><scope>EVB</scope></search><sort><creationdate>20240918</creationdate><title>MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF</title><author>PALOMEQUE ALARCON, José Ángel ; ALBANELL MESTRES, Joan ; PÉREZ NÚÑEZ, Iván ; SERRA MIR, Gabriel ; CELIÀ TERRASSA, Antoni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4431153A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PALOMEQUE ALARCON, José Ángel</creatorcontrib><creatorcontrib>ALBANELL MESTRES, Joan</creatorcontrib><creatorcontrib>PÉREZ NÚÑEZ, Iván</creatorcontrib><creatorcontrib>SERRA MIR, Gabriel</creatorcontrib><creatorcontrib>CELIÀ TERRASSA, Antoni</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PALOMEQUE ALARCON, José Ángel</au><au>ALBANELL MESTRES, Joan</au><au>PÉREZ NÚÑEZ, Iván</au><au>SERRA MIR, Gabriel</au><au>CELIÀ TERRASSA, Antoni</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF</title><date>2024-09-18</date><risdate>2024</risdate><abstract>The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing/presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP4431153A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title MUTANTS OF A LIGAND-DEPENDENT COREPRESSOR (LCOR) AND USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A24%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PALOMEQUE%20ALARCON,%20Jos%C3%A9%20%C3%81ngel&rft.date=2024-09-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4431153A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true